Protara's $45M placement; Plus, news about Eupraxia and GenSight

2024-04-05

临床2期

Protara Therapeutics raises $45M private placement: The oversubscribed financing transaction is set to close April 10. The proceeds should extend the company’s runway through 2026 and help fund an ongoing Phase 2 trial of TARA-002 in high-risk non-muscle invasive bladder cancer. — Ayisha Sharma

Eupraxia Pharmaceuticals makes Nasdaq debut: The Canadian company, which focuses on developing treatments for inflammatory joint conditions and cancer, is now trading under the ticker $EPRX. Eupraxia is using its so-called Diffusphere technology to enable targeted delivery of active ingredients with extended effect duration and “tunable” PK profiles. — Ayisha Sharma

Protara's $45M placement; Plus, news about Eupraxia and GenSight

Preview

来源: EndPoints

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构